Multiple Sclerosis Serum
Multiple Sclerosis Serum from IRB-consented donors with clinically confirmed MS, stratifiable by disease course, EDSS, and disease-modifying therapy. Ideal for serum neurofilament light chain and GFAP work, AQP4/MOG differential serology, and paired serum–CSF studies.
| Lot # | Condition | Volume | Race/Ethnicity | Age | Gender | Country of Collection | Medications | Vials | Price | Action |
|---|---|---|---|---|---|---|---|---|---|---|
| 74781 | Multiple Sclerosis | 1.0 ML | Asian/Pacific Islander | 31 | Male | United States |
No medications
|
6 | $316.00 | |
| 73001 | Multiple Sclerosis | 1.0 ML | Caucasian | 66 | Female | United States |
Pregabalin 300 mg 1x/day Hydrocodone 10mg w/325mg Tylenol - 2x, maybe 3x/day
|
2 | $316.00 | |
| 72917 | Multiple Sclerosis | 1.0 ML | Caucasian | 50 | Male | United States |
Ocrevus 600mg - infusion twice a year Aricept 10mg QD Baclofen 30mg BID Trospium chloride 20mg BID Cymbalta 60mg QD
|
4 | $316.00 | |
| 67899 | Multiple Sclerosis | 1.0 ML | Caucasian | 55 | Female | United States |
2025- Ocrevus twice a year. Modafanil 2x daily 200mg. Rosuvastatin 10 mg daily. VitaminD 50000 units weekly. Magnesium. Ozempic 50 mg a week. Metformin 1000mg daily. . tysabri QM Injection modafanil 200mg BID Vitamin D QD Iron supplement QD B12 gabapentin QD
|
5 | $316.00 | |
| 67415 | Multiple Sclerosis | 1.0 ML | Caucasian | 48 | Female | United States |
Tecfidera/240mg/BID Ocrevus
|
3 | $316.00 | |
| 67521 | Multiple Sclerosis | 1.0 ML | Caucasian | 37 | Female | United States |
2025- Kesimpta (once a month), fluoxetine 40 mg, synthroid 50 mcg, beyaz, 4AP, magnesium oxidize Tysabri IV Q28Days Prozac 40 mg po QD Synthroid 50mcg Gabapentin 200mg PRN
|
3 | $316.00 | |
| 67555 | Multiple Sclerosis | 1.0 ML | Caucasian African American Other | 41 | Female | United States |
Doxycycline Spironolactone
|
3 | $316.00 | |
| 67712 | Multiple Sclerosis | 1.0 ML | Caucasian Hispanic/Latino | 64 | Female | United States |
Centrum 50+women, calcium, omega 3, D3, women’s probiotic
|
3 | $316.00 | |
| 67448 | Multiple Sclerosis | 1.0 ML | Caucasian | 55 | Female | United States |
HTZ 25mg daily, Ampyra, Brupropion 100mg b.i.d., Duloxetine 60mg daily, Baclofen 20mg 2-3 tabs at bedtime, Vit D2 50000 iu, fish oil, vit B12 1000mg/day, Kesimpta injections Q1M Baclofen 40 mg po QD HCTZ 12.5 mg po QD Cymbalta 60mg po QD Ampyra (generic) 10mg QD Wellbutrin 100mg BID Allergy pill (allergra) QD 5000IUD Vitamin D QD Vitamin B12 1000mcg QD
|
3 | $316.00 | |
| 67536 | Multiple Sclerosis | 1.0 ML | Hispanic/Latino | 41 | Male | United States |
2025- Baclofen 20mg 3× a day, tizanidine 4mg twice a daya Baclofen 20mg TID Tizanidine 5mg QD Zyrtec 10 mg QD Atorvastatin Fluoxetine
|
1 | $316.00 |
Human Multiple Sclerosis Serum for Neuroimmunology and Neurodegeneration Research
Our Multiple Sclerosis Serum is sourced from IRB-consented donors clinically diagnosed with multiple sclerosis (MS). Each sample is processed and frozen within 24 hours of collection to preserve neuroaxonal damage markers, immunoglobulins, cytokines, and viral serology for neuroimmunology research.
Why Serum for Multiple Sclerosis Research
MS is an immune-mediated, autoimmune demyelinating disease of the central nervous system driven by autoreactive T cells and B cells that cross the blood–brain barrier. It is not a classical autoantibody-mediated disease — no single pathogenic autoantibody defines it — and serum is valuable for a different reason: it now carries validated markers of the tissue damage the immune attack produces.
- Serum neurofilament light chain — sNfL is the best-established blood biomarker of ongoing neuroaxonal injury in MS, and its measurement in serum has largely replaced the need for cerebrospinal fluid for this purpose
- Glial injury markers — serum GFAP reflects astroglial pathology and is of particular interest in progressive disease
- Serum is required to exclude MS mimics — anti-aquaporin-4 and anti-MOG antibody testing on serum distinguishes neuromyelitis optica spectrum disorder and MOG antibody–associated disease from MS, which makes serologically characterised MS cohorts genuinely valuable
- Paired serum is needed for intrathecal synthesis — oligoclonal bands and the IgG index are cerebrospinal fluid findings that can only be interpreted against a simultaneous serum sample, so serum is not optional in CSF-based MS work
- Epstein–Barr virus serology — anti-EBNA1 antibody responses are among the most strongly established environmental risk associations in MS, and are measured in serum
- Therapy monitoring analytes — anti-drug antibodies against disease-modifying therapies and JC virus antibody status for risk stratification are serum-based measurements central to treatment research
Donor Stratification Available
- Disease course — relapsing-remitting, secondary progressive, or primary progressive MS
- Disability level — EDSS score where recorded
- Clinical state at draw — active relapse versus clinical remission
- Disease-modifying therapy — treatment-naive, or on interferon beta, glatiramer acetate, fumarate, S1P receptor modulator, natalizumab, or anti-CD20 therapy
- Disease duration and radiological activity — time since diagnosis, and MRI lesion activity where available
- Paired specimen availability — matched cerebrospinal fluid from the same donor where collected
- Matched healthy controls available — demographically matched healthy donor serum
Product Features
- Collected from clinically confirmed MS donors
- Processed and frozen within 24 hours of collection
- Research Use Only (RUO)
- Standard and custom aliquot volumes available
- IRB-approved protocols with documented consent
De-identified Donor Data
- Diagnosis confirmation and disease course where classified
- Age, sex assigned at birth, and ethnicity
- Donor-reported allergy, medication, and infectious disease history
- Disease-modifying therapy history and clinical values available on request
Applications
- Serum neurofilament light chain and GFAP measurement and assay development
- Neuroaxonal damage and disease progression biomarker discovery
- Anti-AQP4 and anti-MOG serology for differential diagnosis research
- Paired serum and CSF studies of intrathecal immunoglobulin synthesis
- Epstein–Barr virus and viral risk-factor serology
- Cytokine, chemokine, and inflammatory protein profiling
- Disease-modifying therapy response, anti-drug antibody, and JCV risk research
- Therapeutic candidate screening and validation
Other Multiple Sclerosis Specimen Types
Matched material from the same MS donor pool is available as multiple sclerosis plasma, whole blood, PBMC, leukopak, and cerebrospinal fluid. Course-specific cohorts are available as relapsing-remitting MS serum and secondary progressive MS serum.
Compliance and Quality Assurance
- IRB-approved and HIPAA-compliant protocols
- Electronic informed consent with 21 CFR Part 11 – compliant e-signatures
- Documentation support available for regulatory review
Ordering & Customization
Multiple sclerosis serum is available in standard and custom volumes. For pricing, international orders, or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. To browse the full specimen range and healthy-donor controls, see our human serum collection.
Protocols & Documentation
-
Download
Serum Isolation
Protocol for serum preparation from whole blood, including collection handling, clarification, and quality documentation.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
Serum
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
YES – all our products are research use only (RUO).
1 Answer
You can find our full product catalog here.
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: Quality and Compliance
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Ask a Question
Need a custom Serum cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.